The investment will support the continued advancement of Discovery Evolution’s proprietary RedQueen platform and the initiation of the company’s internal therapeutic discovery pipeline. By combining digital evolution, computational biophysics, and artificial intelligence, RedQueen enables the discovery of therapeutic antibodies against some of the most challenging drug targets, including G protein-coupled receptors (GPCRs).
The partnership reflects a shared ambition to build globally competitive deep-tech companies originating from Central and Eastern Europe.
“Discovery Evolution represents exactly the kind of deep-tech innovation with global potential that STRT Invest specifically seeks in the Central and Eastern European region. By combining AI and digital modeling, the team is transforming a traditionally slow and expensive process, where time and cost savings can ultimately be measured in human lives. We are convinced that the RedQueen platform brings a new dynamic to complex drug discovery, and we are backing their international expansion with capital, an extensive network, and strategic support.” said Peter Langmar, Investment Director of STRT Invest.
Drug discovery remains a lengthy and expensive process, particularly for complex membrane proteins such as GPCRs, which account for approximately one-third of all approved drug targets yet remain difficult to address using conventional antibody discovery technologies. Discovery Evolution tackles this challenge by shifting much of the discovery process from the laboratory into a computational environment, dramatically accelerating candidate generation while reducing experimental costs.
“We are delighted to welcome STRT Invest as a strategic partner,” said Harold P. de Vladár, Founder and CEO of Discovery Evolution. “Beyond capital, STRT brings entrepreneurial experience, an exceptional network, and a long-term commitment to helping technology companies scale internationally. This investment strengthens our ability to further develop RedQueen, expand our discovery pipeline, and accelerate collaborations with pharmaceutical partners.”
Since its founding, Discovery Evolution has successfully generated and experimentally validated antibodies discovered through its RedQueen platform and continues to expand its capabilities in the discovery of therapeutics against GPCRs and other challenging membrane proteins. In parallel, the company has secured competitive non-dilutive funding from the Austrian Research Promotion Agency (FFG) and aws (Austria Wirtschaftsservice), providing further validation of its technology and supporting the continued development of its RedQueen platform and next-generation state-specific antibody discovery capabilities.